

SPECIALTY GUIDELINE MANAGEMENT

ONCASPAR (pegaspargase)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

A. Acute lymphoblastic leukemia (ALL)

- Oncaspar is indicated as a component of a multi-agent chemotherapeutic regimen for the first line treatment of patients with ALL.

- Oncaspar is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with ALL and hypersensitivity to native forms of L-asparaginase.

B. Compendial Uses

1. Extranodal natural killer/T-cell lymphoma – nasal type
2. Lymphoblastic lymphoma (managed in the same manner as ALL)

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR APPROVAL

A. **Acute lymphoblastic leukemia and lymphoblastic lymphoma**

Authorization of 12 months may be granted for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma when Oncaspar is used in conjunction with multi-agent chemotherapy.

B. **Extranodal natural killer/T-cell lymphoma-nasal type**

Authorization of 12 months may be granted for the treatment of extranodal natural killer/T-cell lymphoma-nasal type when Oncaspar is used in conjunction with multi-agent chemotherapy.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

IV. REFERENCES

1. Oncaspar [package insert]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals, Inc.; May 2015.
2. The NCCN Drugs & Biologics Compendium™ © 2016 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed August 19, 2016.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2016. http://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed August 19, 2016.